Last update 21 Nov 2024

Opevesostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Target
Mechanism
CYP11A1 inhibitors(Cytochrome P450 11A1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC21H26N2O5S
InChIKeyLHVKCOBGLZGRQZ-UHFFFAOYSA-N
CAS Registry2231294-96-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 3
CA
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
CL
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
ES
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
CL
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
IT
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
AU
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
FR
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
SG
18 Dec 2023
Metastatic castration-resistant prostate cancerPhase 3
US
18 Dec 2023
Prostatic CancerPhase 3
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
134
(AR-LBD mutation-positive)
(awshvlizcs) = fezrgzwbwx hzwgujryul (vjuatlopim )
Positive
15 Sep 2024
Opevesostat 5mg BID
(AR-LBD mutation-negative)
(awshvlizcs) = zqrolfjahv hzwgujryul (vjuatlopim )
Phase 2
134
MK-5684 5mg BID
(AR-LBD mutation-positive)
(oxjmrpkevm) = ucaottjsoy ptjfnolxnb (qilakckhwo )
Positive
25 Jan 2024
(AR-LBD mutation-negative)
(yzblpkcnmv) = ddswmgvnpo aihiyuijdk (aljjblihgj )
Phase 1/2
102
ODM-208(phase Ⅰ) + dexamethasone 1 mg/fludrocortisone 0.1 mg
(aieokjbfni) = fypmkypsxx kokoirzzjd (rjgvtrrobe )
Positive
01 Jan 2024
ODM-208(phase Ⅱ)+ dexamethasone 1 mg/fludrocortisone 0.1 mg
(aieokjbfni) = ncrezfkkdd kokoirzzjd (rjgvtrrobe )
Phase 1/2
92
ODM-208+glucocorticoid/mineralocorticoid replacement+androgen deprivation therapy
(ARmut in phase 1)
(hytdgpxxbt) = Treatment-related adrenal insufficiency was the most common toxicity in phase 1 (n=17, 36.2%; necessitating ODM-208 discontinuation in one patient); this toxicity occurred in six patients (13.3%) at 5 mg twice a day in phase 2. rsmexqcaji (xgkulmcvep )
Positive
26 Dec 2023
ODM-208+glucocorticoid/mineralocorticoid replacement+androgen deprivation therapy
(AR wild type in phase 1)
Phase 2
45
(qekjmbydnr) = jsumphkhsm jnwpvwyeht (bwpxgqdqrv )
Positive
11 Sep 2022
Phase 1/2
44
(gsghmxthft) = severe adrenal insufficiency 32% zkipvqtcnw (cfundsvcqg )
Positive
18 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free